|
|
 |
|
Viewing report
|
|
|
|
Renal Cell Carcinoma Cancer Drug Futures 2010
Espicom Business Intelligence Ltd, Oct 2010, Pages: 178
The number of renal cell carcinoma (RCC) patients by value, in the US, Europe and Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to approximately 832,000 in 2015). Approximately 18% of the RCC patient population currently receives drug therapy but, by 2015, this percentage is expected to grow reflecting an increase in the number of treatment options, improvements in drug efficacy and the use of drug therapy earlier in the course of the disease.
The total RCC sales for branded products will increase substantially from almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%. Sales will be driven by the new targeted therapies which will account for sales of around US$6.1 billion in 2015,
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service, Renal Cell Carcinoma Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN:
- Track the drug’s progress and stay abreast of developments
- Understand the drug’s novelty and mode of action
- Evaluate the strength of the company developing/producing the drug
- Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
- Know the launch timeframe for new products or indications
- Be aware of promising mid-stage development candidates
- Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
- Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include:
- Novelty/rationale for mechanism of action
- Current status
- Proof of concept/clinical data
- Development risks
- Company expertise
- Competition within the market-place
- Sales forecast (for key late-stage and launched products)
- Competitor ratio analysis score
- Clinical trial results
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
MRSA Drug Futures
CNS Drug Discoveries: What the future holds 2008
New Drug Futures 2009
CNS Drug Discoveries: Multiple Sclerosis Chapter
Monoclonal Antibodies: what the future holds
CNS Drug Discoveries: Schizophrenia Chapter
The executive guide to Heat Shock Proteins
Obesity Drug Discoveries: what the future holds
Clinical Operations: Benchmarking Per-Patient Trial Costs, Staffing and Adaptive Design
Kidney Cancer Drugs - Global Strategic Business Report
|
|
|
|
